Suppr超能文献

通过比较晶体学分析揭示雌激素受体配体的核因子κB选择性

NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses.

作者信息

Nettles Kendall W, Bruning John B, Gil German, Nowak Jason, Sharma Sanjay K, Hahm Johnnie B, Kulp Kristen, Hochberg Richard B, Zhou Haibing, Katzenellenbogen John A, Katzenellenbogen Benita S, Kim Younchang, Joachmiak Andrzej, Greene Geoffrey L

机构信息

Department of Cancer Biology, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, Florida 33458, USA.

出版信息

Nat Chem Biol. 2008 Apr;4(4):241-7. doi: 10.1038/nchembio.76. Epub 2008 Mar 16.

Abstract

Our understanding of how steroid hormones regulate physiological functions has been significantly advanced by structural biology approaches. However, progress has been hampered by misfolding of the ligand binding domains in heterologous expression systems and by conformational flexibility that interferes with crystallization. Here, we show that protein folding problems that are common to steroid hormone receptors are circumvented by mutations that stabilize well-characterized conformations of the receptor. We use this approach to present the structure of an apo steroid receptor that reveals a ligand-accessible channel allowing soaking of preformed crystals. Furthermore, crystallization of different pharmacological classes of compounds allowed us to define the structural basis of NFkappaB-selective signaling through the estrogen receptor, thus revealing a unique conformation of the receptor that allows selective suppression of inflammatory gene expression. The ability to crystallize many receptor-ligand complexes with distinct pharmacophores allows one to define structural features of signaling specificity that would not be apparent in a single structure.

摘要

结构生物学方法极大地推动了我们对类固醇激素如何调节生理功能的理解。然而,异源表达系统中配体结合域的错误折叠以及干扰结晶的构象灵活性阻碍了研究进展。在此,我们表明,类固醇激素受体常见的蛋白质折叠问题可通过稳定受体特征明确构象的突变来规避。我们运用这种方法展示了无配体类固醇受体的结构,该结构揭示了一个配体可及通道,允许预先形成的晶体进行浸泡。此外,不同药理类化合物的结晶使我们能够确定通过雌激素受体进行NFκB选择性信号传导的结构基础,从而揭示了受体的独特构象,该构象允许选择性抑制炎症基因表达。能够使许多具有不同药效基团的受体 - 配体复合物结晶,使得人们能够定义信号特异性的结构特征,而这些特征在单一结构中并不明显。

相似文献

1
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses.
Nat Chem Biol. 2008 Apr;4(4):241-7. doi: 10.1038/nchembio.76. Epub 2008 Mar 16.
2
Coupling of receptor conformation and ligand orientation determine graded activity.
Nat Chem Biol. 2010 Nov;6(11):837-43. doi: 10.1038/nchembio.451. Epub 2010 Oct 10.
3
Pyrazolo[1,5-a]pyrimidines as estrogen receptor ligands: defining the orientation of a novel heterocyclic core.
Bioorg Med Chem Lett. 2004 Nov 15;14(22):5681-4. doi: 10.1016/j.bmcl.2004.08.046.
4
CoMFA and docking study of novel estrogen receptor subtype selective ligands.
J Comput Aided Mol Des. 2003 May-Jun;17(5-6):313-28. doi: 10.1023/a:1026104924132.
8
Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
PLoS One. 2015 Jul 2;10(7):e0132221. doi: 10.1371/journal.pone.0132221. eCollection 2015.
9

引用本文的文献

2
Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.
Front Oncol. 2025 Jun 26;15:1513225. doi: 10.3389/fonc.2025.1513225. eCollection 2025.
3
Entropy tree networks of residue dynamics encode protein allostery.
bioRxiv. 2025 May 30:2025.05.28.656549. doi: 10.1101/2025.05.28.656549.
5
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer.
Biomedicines. 2024 Nov 26;12(12):2700. doi: 10.3390/biomedicines12122700.
6
Cadmium activation of wild-type and constitutively active estrogen receptor alpha.
Front Endocrinol (Lausanne). 2024 Aug 9;15:1380047. doi: 10.3389/fendo.2024.1380047. eCollection 2024.
7
Asymmetric allostery in estrogen receptor-α homodimers drives responses to the ensemble of estrogens in the hormonal milieu.
Proc Natl Acad Sci U S A. 2024 Jun 11;121(24):e2321344121. doi: 10.1073/pnas.2321344121. Epub 2024 Jun 3.
8
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.
Endocrinology. 2024 Apr 29;165(6). doi: 10.1210/endocr/bqae051.

本文引用的文献

1
Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Structure. 2007 Oct;15(10):1258-71. doi: 10.1016/j.str.2007.07.014.
2
CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor.
Mol Endocrinol. 2008 Feb;22(2):263-72. doi: 10.1210/me.2007-0324. Epub 2007 Oct 11.
4
Structural plasticity in the oestrogen receptor ligand-binding domain.
EMBO Rep. 2007 Jun;8(6):563-8. doi: 10.1038/sj.embor.7400963. Epub 2007 Apr 27.
6
Hormone-PAMAM dendrimer conjugates: polymer dynamics and tether structure affect ligand access to receptors.
Angew Chem Int Ed Engl. 2006 Nov 6;45(43):7243-8. doi: 10.1002/anie.200601923.
7
Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity.
J Biol Chem. 2006 Jun 30;281(26):17909-19. doi: 10.1074/jbc.M513684200. Epub 2006 Apr 28.
10
A fully dissociated compound of plant origin for inflammatory gene repression.
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15827-32. doi: 10.1073/pnas.0505554102. Epub 2005 Oct 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验